Home > Pulmonology > ERS 2018 > COPD: Triple therapy, MABA and antibiotics > Landmark Triple Therapy Trials

Landmark Triple Therapy Trials

Presented By
Prof. Leonardo Fabbri, Dr Konstantinos Kostikas
Conference
ERS 2018
Trial
IMPACT, FLAME, RCTs, TRILOGY, TRINITY, TRIBUTE

State-of-the-art

By 2020, chronic obstructive pulmonary disease (COPD) is projected to become the third leading cause of death worldwide [1]. Every year, more than 3 million people worldwide die due to this chronic condition. Patients with COPD have a significantly shorter survival than comorbidity-matched controls [2]. Most common causes of death in patients with COPD are non-respiratory, particularly cardiovascular diseases (myocardial infarction and stroke) and cancer [2]. Previous exacerbations and hospitalisations, comorbidities, reduced lung function, and poor health status are the strongest predictors of death in patients with COPD [3]. Although the treatment of symptoms and prevention of acute exacerbations has improved, few advances have been made to stop disease progression or prevent mortality. To reduce disease burden, smoking cessation, increasing physical activity, and early detection and treatment of comorbidities are essential. A global pol...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on